|
1
|
Mamelak AN and Jacoby DB: Targeted
delivery of antitumoral therapy to glioma and other malignancies
with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv.
4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 17
Suppl 4:iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY and Reardon DA: Neuro-oncology in
2015: Progress in glioma diagnosis, classification and treatment.
Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McGuire S: World cancer report 2014.
Geneva, Switzerland: World health organization, international
agency for research on cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weller M, Stupp R, Reifenberger G, Brandes
AA, van den Bent MJ, Wick W and Hegi ME: MGMT promoter
methylation in malignant gliomas: Ready for personalized medicine?
Nat Rev Neurol. 6:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wick W, Weller M, van den Bent M, Sanson
M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M and
Reifenberger G: MGMT testing - the challenges for
biomarker-based glioma treatment. Nat Rev Neurol. 10:372–385. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Hagan HM, Mohammad HP and Baylin SB:
Double strand breaks can initiate gene silencing and
SIRT1-dependent onset of DNA methylation in an exogenous promoter
CpG island. PLoS Genet. 4:e10001552008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu
P and Kang C: EZH2 is a negative prognostic factor and exhibits
pro-oncogenic activity in glioblastoma. Cancer Lett. 356:929–936.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ku BM, Lee YK, Ryu J, Jeong JY, Choi J,
Eun KM, Shin HY, Kim DG, Hwang EM, Yoo JC, et al: CHI3L1 (YKL-40)
is expressed in human gliomas and regulates the invasion, growth
and survival of glioma cells. Int J Cancer. 128:1316–1326. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steponaitis G, Skiriutė D, Kazlauskas A,
Golubickaitė I, Stakaitis R, Tamašauskas A and Vaitkienė P: High
CHI3L1 expression is associated with glioma patient
survival. Diagn Pathol. 11:422016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ji T, Liu D, Shao W, Yang W, Wu H and Bian
X: Decreased expression of LATS1 is correlated with the progression
and prognosis of glioma. J Exp Clin Cancer Res. 31:672012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goidts V, Bageritz J, Puccio L, Nakata S,
Zapatka M, Barbus S, Toedt G, Campos B, Korshunov A, Momma S, et
al: RNAi screening in glioma stem-like cells identifies PFKFB4 as a
key molecule important for cancer cell survival. Oncogene.
31:3235–3243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li PCH: Overview of microarray technology.
Microarray Technology: Methods and Applications. Li PCH, Sedighi A
and Wang L: 1368. 1st. Humana Press, Inc.; Totowa, NJ: pp. 3–4.
2016, View Article : Google Scholar
|
|
14
|
Naidu CN and Suneetha Y: Review article:
Current knowledge on microarray technology-an overview. Trop J
Pharm Res. 11:1532012. View Article : Google Scholar
|
|
15
|
Teschendorff AE, Marabita F, Lechner M,
Bartlett T, Tegner J, Gomez-Cabrero D and Beck S: A beta-mixture
quantile normalization method for correcting probe design bias in
Illumina Infinium 450 k DNA methylation data. Bioinformatics.
29:189–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brandes AA, Franceschi E, Paccapelo A,
Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza
G, Silini EM, et al: Role of MGMT methylation status at time
of diagnosis and recurrence for patients with glioblastoma:
Clinical implications. Oncologist. 22:432–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pesarin F and Salmaso L: The permutation
testing approach: A review. Statistica. 70:481–509. 2013.
|
|
18
|
Wiens TS, Dale BC, Boyce MS and Kershaw
GP: Three way k-fold cross-validation of resource selection
functions. Ecological Modelling. 212:244–255. 2008. View Article : Google Scholar
|
|
19
|
Lacny S, Wilson T, Clement F, Roberts DJ,
Faris PD, Ghali WA and Marshall DA: Kaplan-meier survival analysis
overestimates the risk of revision arthroplasty: A meta-analysis.
Clin Orthop Relat Res. 473:3443–3445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perolat J, Couso I, Loquin K and Strauss
O: Generalizing the Wilcoxon rank-sum test for interval data. Int J
Approximate Reasoning. 56:108–121. 2015. View Article : Google Scholar
|
|
21
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lambiv WL, Vassallo I, Delorenzi M, Shay
T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E,
Hamou MF, et al: The Wnt inhibitory factor 1 (WIF1) is targeted in
glioblastoma and has a tumor suppressing function potentially by
induction of senescence. Neuro Oncol. 13:736–747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murat A, Migliavacca E, Gorlia T, Lambiv
WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven
MC, et al: Stem cell-related ‘self-renewal’ signature and high
epidermal growth factor receptor expression associated with
resistance to concomitant chemoradiotherapy in glioblastoma. J Clin
Oncol. 26:3015–3024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mizukami A, Matsue Y, Naruse Y, Kowase S,
Kurosaki K, Suzuki M, Matsumura A, Nogami A, Aonuma K and Hashimoto
Y: Kaplan-Meier survival analysis and Cox regression analyses
regarding right ventricular septal pacing: Data from Japanese
pacemaker cohort. Data Brief. 8:1303–1307. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bigarella CL, Borges L, Costa FF and Saad
ST: ARHGAP21 modulates FAK activity and impairs glioblastoma cell
migration. Biochim Biophys Acta. 1793:806–816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Banting GS, Barak O, Ames TM, Burnham AC,
Kardel MD, Cooch NS, Davidson CE, Godbout R, McDermid HE and
Shiekhattar R: CECR2, a protein involved in neurulation, forms a
novel chromatin remodeling complex with SNF2L. Hum Mol Genet.
14:513–524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirabayashi T and Yagi T: Protocadherins
in neurological diseases. Adv Neurobiol. 8:293–314. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shan M, Su Y, Kang W, Gao R, Li X and
Zhang G: Aberrant expression and functions of protocadherins in
human malignant tumors. Tumor Biol. 37:12969–12981. 2016.
View Article : Google Scholar
|
|
29
|
Sui X, Wang D, Geng S, Zhou G, He C and Hu
X: Methylated promoters of genes encoding protocadherins as a new
cancer biomarker family. Mol Biol Rep. 39:1105–1111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Villalva C, Cortes U, Wager M, Tourani JM,
Rivet P, Marquant C, Martin S, Turhan AG and Karayan-Tapon L:
O6-Methylguanine-methyltransferase (MGMT) promoter methylation
status in glioma stem-like cells is correlated to temozolomide
sensitivity under differentiation-promoting conditions. Int J Mol
Sci. 13:6983–6994. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fiano V, Trevisan M, Trevisan E, Senetta
R, Castiglione A, Sacerdote C, Gillio-Tos A, De Marco L, Grasso C,
Magistrello M, et al: MGMT promoter methylation in plasma of glioma
patients receiving temozolomide. J Neurooncol. 117:347–357. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Steinbrenner H and Sies H: Selenium
homeostasis and antioxidant selenoproteins in brain: Implications
for disorders in the central nervous system. Arch Biochem Biophys.
536:152–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pitts MW, Byrns CN, Ogawa-Wong AN, Kremer
P and Berry MJ: Selenoproteins in nervous system development and
function. Biol Trace Elem Res. 161:231–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Steinbrenner H, Alili L, Bilgic E, Sies H
and Brenneisen P: Involvement of selenoprotein P in protection of
human astrocytes from oxidative damage. Free Radic Biol Med.
40:1513–1523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang X, Hill KE, Maguire MJ and Burk RF:
Synthesis and secretion of selenoprotein P by cultured rat
astrocytes. Biochim Biophys Acta. 1474:390–396. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du X, Li H, Wang Z, Qiu S, Liu Q and Ni J:
Selenoprotein P and selenoprotein M block Zn2+ -mediated
Aβ42 aggregation and toxicity. Metallomics. 5:861–870.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yi F, Ni W, Liu W, Pan X, Han X, Yang L,
Kong X, Ma R and Chang R: SPAG9 is overexpressed in human
astrocytoma and promotes cell proliferation and invasion. Tumour
Biol. 34:2849–2855. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang J, Liu Y, Fang W and Liu F:
Sperm-associated antigen 9 promotes astrocytoma cell invasion
through the upregulation of podocalyxin. Mol Med Rep. 10:417–422.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ando K, Uemura K, Kuzuya A, Maesako M,
Asada-Utsugi M, Kubota M, Aoyagi N, Yoshioka K, Okawa K, Inoue H,
et al: N-cadherin regulates p38 MAPK signaling via association with
JNK-associated leucine zipper protein: Implications for
neurodegeneration in Alzheimer disease. J Biol Chem. 286:7619–7628.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu H, Chen Y, Tan C, Xu T, Yan Y, Qin R,
Huang Q, Lu C, Liang C, Lu Y, et al: High expression of WDR1 in
primary glioblastoma is associated with poor prognosis. Am J Transl
Res. 8:1253–1264. 2016.PubMed/NCBI
|
|
41
|
Xie X, Wang Z and Chen Y: Association of
LKB1 with a WD-repeat protein WDR6 is implicated in cell growth
arrest and p27Kip1 induction. Mol Cell Biochem.
301:115–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome-biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Karpf AR and Matsui S: Genetic disruption
of cytosine DNA methyltransferase enzymes induces chromosomal
instability in human cancer cells. Cancer Res. 65:8635–8639. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Etcheverry A, Aubry M, de Tayrac M,
Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L,
Menei P, et al: DNA methylation in glioblastoma: Impact on gene
expression and clinical outcome. BMC Genomics. 11:7012010.
View Article : Google Scholar : PubMed/NCBI
|
